STERIS Corporation (NYSE: STE), a leader in infection prevention and surgical technologies, has reached a new 52-week high, with its stock price soaring to $245.93. This milestone reflects a significant uptrend in the company's market performance, underpinned by a solid 1-year change of 10.03%. Investors have shown increased confidence in STERIS's growth trajectory and market position, as the company continues to innovate and expand its product offerings in the healthcare sector. The new 52-week high represents a notable achievement for STERIS, signaling strong investor optimism about the company's future prospects.
In other recent news, STERIS Plc reported a strong first-quarter performance for 2025, with an 8% increase in total revenue and a 10% rise in adjusted earnings per share to $2.03. The company's net income reached $201.7 million, and its total debt decreased to $2.3 billion. In addition, STERIS announced its 19th consecutive year of dividend increases and unveiled a $100 million restructuring plan aimed at enhancing operations.
KeyBanc has raised the price target on STERIS shares from $255.00 to $265.00, maintaining an Overweight rating. This revision follows meetings with the company's management, which assured KeyBanc of STERIS's positive financial outlook for fiscal year 2025.
Despite potential cutbacks in the pharma and bio pharma industries, STERIS is experiencing strong growth in its services and consumables businesses and reported mid-single-digit order growth and a $350 million backlog in the healthcare equipment segment. The company's $100 million restructuring plan is expected to yield most benefits in fiscal year 2026. These are the recent developments for STERIS Plc.
InvestingPro Insights
As STERIS Corporation (NYSE: STE) celebrates its new 52-week high, the company's financial health and market performance offer additional insights for investors. With a robust market capitalization of $24.2 billion, STERIS stands out in the healthcare sector. The company's price-to-earnings (P/E) ratio, which currently stands at 60.54, suggests a premium valuation that investors are willing to pay for its earnings. However, when looking at the adjusted P/E ratio for the last twelve months as of Q1 2025, the figure is more grounded at 37.35, indicating a potentially more reasonable valuation in the context of its earnings growth.
Investors seeking stability might appreciate that STERIS has raised its dividend for 13 consecutive years, demonstrating a commitment to shareholder returns. This commitment is further underscored by the company's dividend yield of 0.95% and a significant dividend growth of 21.28% in the last twelve months as of Q1 2025. Additionally, STERIS's liquid assets exceed its short-term obligations, which provides a cushion for the company to manage its financial obligations and invest in future growth.
For those interested in further analysis, there are more InvestingPro Tips available, offering deeper insights into STERIS's performance and potential investment opportunities. Visit InvestingPro for additional tips and real-time data to inform your investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.